Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. (May 2020)

• Record Type: Journal Article
• Authors: Abd El Aziz, Mohamed A; Sacco, Rodolfo; Facciorusso, Antonio
• Is Part Of: Antiviral chemistry & chemotherapy. Volume 28(2020)
• Publication Date: 2020-05
• Subjects: Hepatocellular carcinoma -- Hepatitis B virus -- nucleos(t)ide analogues -- lamivudine -- adefovir -- entecavir -- tenofovir -- telbivudine interferon; Antiviral agents -- Periodicals; Chemotherapy -- Periodicals; 615.7924
• DOI: 10.1177/2040206620921331
• Languages: English
• ISSNs: 0956-3202

Abstract

Hepatitis B virus is mainly considered to cause hepatocellular carcinoma which is the fourth leading cause of cancer-related mortality worldwide. Treatment of Hepatitis B virus with nucleos(t)ide analogues can decrease the progression of the disease and subsequently decreases the incidence of hepatocellular carcinoma. In this review, we have discussed the different classes of nucleos(t)ide analogues used in the treatment of Hepatitis B virus and their relationship with the development of hepatocellular carcinoma. Furthermore, we discussed the effect of treatment of Hepatitis B virus with Nucleoside analogues (NAs) before, during and after surgery, chemoembolization, radiofrequency ablation, and chemotherapy for the treatment of hepatocellular carcinoma.